PrEP goes local: Community-Based HIV prevention trial launches in rio

NCT ID NCT07584122

Recruiting now Prevention Sponsor: Oswaldo Cruz Foundation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to make HIV prevention easier to access for underserved groups in Rio de Janeiro, such as gay and bisexual men, transgender women, and sex workers. Instead of requiring clinic visits, participants can get daily PrEP pills and support through community organizations, mobile units, or telehealth. Researchers will see if this approach helps more people start and stay on PrEP, with the goal of reducing new HIV infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) oral PrEP
What this could lead to: If successful, this could show that offering PrEP in community settings helps more at-risk people start and stay on HIV prevention, reducing new infections in underserved areas.
What could go wrong: This is an early feasibility study with 400 participants, so results may not apply broadly. Daily pill adherence can be challenging, and the study does not directly measure HIV infection rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Hospital Geral de Nova Iguaçu
RECRUITING

Nova Iguaçu, Rio de Janeiro, 26030-380, Brazil
Instituto Nacional de Infectologia Evandro Chagas
RECRUITING

Rio de Janeiro, Rio de Janeiro, 21040360, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.